BLOOMFIELD, Conn., Dec. 15, 2023 /PRNewswire/ -- To help school-age children and their families better access community resources and support, The Cigna Group Foundation today announced it has committed nearly $3.3 million to reduce food insecurity and support youth mental health. These new grants are part of The Cigna Group Foundation's Healthier Kids For Our Future® initiative, which has awarded $25 million to nearly 150 nonprofits in the United States since 2019.
"It's critical that we help students across the country thrive – academically, physically, and emotionally," said Melissa Skottegaard, chairperson of The Cigna Group Foundation. "The extraordinary organizations are embedded within their local communities, which allows them to know firsthand how to best solve some of these tough challenges. We are energized by the innovation these groups have shown and the continued positive impact they will make."
Some of the organizations that The Cigna Group Foundation partnered with this year are:
About The Cigna Group Foundation
The Cigna Group Foundation is a private foundation funded by contributions from The Cigna Group (NYSE:CI) and its subsidiaries. The Cigna Group Foundation supports organizations sharing its commitment to enhancing the health of individuals and families, and the well-being of their communities, with a special focus on those communities where employees of The Cigna Group live and work.
Media Contact
Kelly Mathews
(423) 260-9267
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$280.00 |
Daily Change: | -1.63 -0.58 |
Daily Volume: | 412,344 |
Market Cap: | US$77.880B |
October 31, 2024 September 12, 2024 September 12, 2024 August 01, 2024 |
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORECue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB